TD Cowen Maintains Buy Ratings on Apple, Agios, Cardinal Health, NOV Amid Growth Potential

TD Cowen maintains a strong bullish outlook on several stocks, particularly highlighting the immense investment potential in artificial intelligence (AI) as a revolutionary force reshaping multiple industries. Agios Pharmaceuticals receives a reiterated Buy rating, with confidence in its mitapivat drug expected to significantly reduce vaso-occlusive crises in sickle cell disease, potentially unlocking a $4 billion market with positive Phase 3 trial results anticipated by the end of 2025. Cardinal Health is also reaffirmed as a Buy, with expectations for increased pharmaceutical profit guidance and new product launches, though AI stocks are noted to offer greater upside potential and lower risk. NOV Inc. is favored for its long-term offshore spending benefits and strong financial health despite near-term challenges, supported by a conservative valuation and expectations for improved margins. Across these sectors, TD Cowen’s analysis underscores the opportunities for growth and value, particularly emphasizing AI as a disruptive force with exponential growth prospects and the potential for substantial investor gains.